Chronic rejection of rat aortic allografts. III. Synthesis of major eicosanoids by vascular wall components and effect of inhibition of the thromboxane cascade.
We have previously demonstrated that rat aortic allografts from the DA (RT1a) to the WF (RT1v) strain develop chronic arteriosclerotic changes in the vascular wall after a short spontaneously reversible acute rejection episode. These changes, which are lacking in syngeneic DA-to-DA control grafts, are virtually identical with those observed in human allografts during chronic rejection. In this study we have investigated whether eicosanoids are involved in the generation of arteriosclerotic changes. Incubation of aortic wall rings in vitro and immunochemical assays demonstrated that the arteriosclerotic allografts synthesize significantly more thromboxane B2 (TxB2) but not 6-ketoprostaglandin F1 alpha (6-keto-PGF1 alpha) or leukotriene B4. The increased synthesis of TxB2 in the allografts persisted for at least 5 months after transplantation. Separate incubation of the two major components of the vascular wall, after microdissection of the intima and (media plus) adventitia, demonstrated that most of the synthesis of TxB2 during chronic rejection was due to the outer layer of aorta, presumably the inflammatory cells of the adventitia. In contrast, most of the 6-keto-PGF1 alpha was synthesized by the inner layer of the aorta, presumably the endothelial cells and the smooth muscle cells of the intima. Administration of 1 mg.kg-1 x day-1 of a specific TxA2 receptor inhibitor, GR32191B, to the recipient rat reduced the proliferative response of inflammatory cells in the adventitia by 30%, as detected by in vivo tritiated-thymidine (3H-TdR) labeling and autoradiography, but did not reduce the proliferative response of smooth muscle cells in the media and intima.(ABSTRACT TRUNCATED AT 250 WORDS)
Mennander
A
A
Transplantation Laboratory, University of Helsinki, Finland.
Tiisala
S
S
Ustinov
J
J
Räisänen
A
A
Paavonen
T
T
Häyry
P
P
D000818:Animals; D001013:Aorta, Thoracic / Q000637:transplantation*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001808:Blood Vessels / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D015777:Eicosanoids / Q000096:biosynthesis*; D006084:Graft Rejection; D006538:Heptanoic Acids / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D017482:Receptors, Thromboxane / Q000187:drug effects*; D013931:Thromboxanes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014184:Transplantation, Homologous
D001713:Biphenyl Compounds; D015777:Eicosanoids; D006538:Heptanoic Acids; D017482:Receptors, Thromboxane; D013931:Thromboxanes; C060013:vapiprost